27th January 2017
Runtime 11:27
Marcelo Bravo, CEO of Oxford Pharmascience Group, talks about the company strategy and its unique opportunity. He highlights the key points of the recent announcement, and answers Investors questions on ongoing commercial discussions, progress on U.S. regulations, and what is expected this year. OXP is a speciality Pharma company which focusses on re-developing existing drugs to limit the side effects and other associated issues.
It works closely with its partners for products commercialisation. In 2017, feedback from the FDA in Q1 will be the critical milestone for the company.
The Company had net cash of circa £21.9 million (at 31/12/2016) and remains well funded to pursue its strategy.
